CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 8 of 8

Some of the metrics are blocked by your
consent settings
Air pollution and hospitalization for acute complications of diabetes in Chile
(2012)
Robert E. Dales
;
Sabit Cakmak
;
Claudia Blanco Vidal
;
Maria Angelica Rubio
10Scopus© Citations 37
Some of the metrics are blocked by your
consent settings
Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review
(2022)
CASTILLO LABORDE, CARLA CECILIA
;
Macarena Hirmas-Adauy
;
MATUTE WILLEMSEM, MARIA ISABEL
;
Anita Jasmen
;
Oscar Urrejola
<jats:p><jats:bold>Objective:</jats:bold> Identify barriers and facilitators in access to medicines for diabetes, hypertension, and dyslipidemia, considering patient, health provider, and health system perspectives.</jats:p><jats:p><jats:bold>Methods:</jats:bold> Scoping review based on Joanna Briggs methodology. The search considered PubMed, Cochrane Library, CINAHL, Academic Search Ultimate, Web of Science, SciELO Citation Index, and grey literature. Two researchers conducted screening and eligibility phases. Data were thematically analyzed.</jats:p><jats:p><jats:bold>Results:</jats:bold> The review included 219 documents. Diabetes was the most studied condition; most of the evidence comes from patients and the United States. Affordability and availability of medicines were the most reported dimension and specific barrier respectively, both cross-cutting concerns. Among high- and middle-income countries, identified barriers were cost of medicines, accompaniment by professionals, long distances to facilities, and cultural aspects; cost of transportation emerges in low-income settings. Facilitators reported were financial accessibility, trained health workers, medicines closer to communities, and patients’ education.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> Barriers and facilitators are determined by socioeconomic and cultural conditions, highlighting the role of health systems in regulatory and policy context (assuring financial coverage and free medicines); providers’ role bringing medicines closer; and patients’ health education and disease management.</jats:p>
Scopus© Citations 12 1
Some of the metrics are blocked by your
consent settings
Interferon-γ and high glucose-induced opening of Cx43 hemichannels causes endothelial cell dysfunction and damage
(2020)
Juan C. Sáez
;
Susana Contreras-Duarte
;
Valeria C. Labra
;
Cristian A. Santibañez
;
Luis A. Mellado
Scopus© Citations 30 2
Some of the metrics are blocked by your
consent settings
Microencapsulation of cellular aggregates composed of differentiated insulin and glucagon-producing cells from human mesenchymal stem cells derived from adipose tissue
(2020)
Claudia Jara
;
Felipe Oyarzun-Ampuero
;
Flavio Carrión
;
Esteban González-Echeverría
;
Claudio Cappelli
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>In type I diabetes mellitus (T1DM) pancreatic β cells are destroyed. Treatment entails exogenous insulin administration and strict diet control, yet optimal glycemic control is hardly attainable. Islet transplant could be an alternative in patients with poor glycemic control, but inefficient islet purification and autoimmune response of patients is still a challenge. For these reasons, it is necessary to explore new cellular sources and immunological isolation methods oriented to develop T1DM cell-based therapies.</jats:p> </jats:sec><jats:sec> <jats:title>Aims</jats:title> <jats:p>We postulate human adipose-derived stem cell (hASC) as an adequate source to generate pancreatic islet cells in vitro, and to produce islet-like structures. Furthermore, we propose microencapsulation of these aggregates as an immunological isolation strategy.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>hASC obtained from lipoaspirated fat tissue from human donors were differentiated in vitro to insulin (Ins) and glucagon (Gcg) producing cells. Then, insulin producing cells (IPC) and glucagon producing cells (GPC) were cocultured in low adhesion conditions to form cellular aggregates, and later encapsulated in a sodium alginate polymer. Expression of pancreatic lineage markers and secretion of insulin or glucagon in vitro were analyzed.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The results show that multipotent hASC efficiently differentiate to IPC and GPC, and express pancreatic markers, including insulin or glucagon hormones which they secrete upon stimulation (fivefold for insulin in IPC, and fourfold for glucagon, compared to undifferentiated cells). In turn, calculation of the Feret diameter and area of cellular aggregates revealed mean diameters of ~ 80 µm, and 65% of the aggregates reached 4000 µm<jats:sup>2</jats:sup> at 72 h of formation. IPC/GPC aggregates were then microencapsulated in sodium-alginate polymer microgels, which were found to be more stable when stabilized with Ba<jats:sup>2+</jats:sup>, yielding average diameters of ~ 300 µm. Interestingly, Ba<jats:sup>2+</jats:sup>-microencapsulated aggregates respond to high external glucose with insulin secretion.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>The IPC/GPC differentiation process from hASC, followed by the generation of cellular aggregates that are later microencapsulated, could represent a possible treatment for T1DM.</jats:p> </jats:sec>
16Scopus© Citations 9
Some of the metrics are blocked by your
consent settings
Medical comorbidity of binge eating disorder
(2016)
Pablo Olguin
;
Manuel Fuentes
;
Guillermo Gabler
;
Anna I. Guerdjikova
;
Paul E. Keck
14Scopus© Citations 100
Some of the metrics are blocked by your
consent settings
Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice
(2016)
EZQUER, EDUARDO MARCELO
;
Cristhian A. Urzua
;
Scarleth Montecino
;
Karla Leal
;
EZQUER, EDUARDO FERNANDO
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Diabetic retinopathy is a common complication of diabetes and the leading cause of irreversible vision loss in the Western world. The reduction in color/contrast sensitivity due to the loss of neural cells in the ganglion cell layer of the retina is an early event in the onset of diabetic retinopathy. Multipotent mesenchymal stromal cells (MSCs) are an attractive tool for the treatment of neurodegenerative diseases, since they could differentiate into neuronal cells, produce high levels of neurotrophic factors and reduce oxidative stress. Our aim was to determine whether the intravitreal administration of adipose-derived MSCs was able to prevent the loss of retinal ganglion cells in diabetic mice.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Diabetes was induced in C57BL6 mice by the administration of streptozotocin. When retinal pro-damage mechanisms were present, animals received a single intravitreal dose of 2 × 10<jats:sup>5</jats:sup> adipose-derived MSCs or the vehicle. Four and 12 weeks later we evaluated: (a) retinal ganglion cell number (immunofluorescence); (b) neurotrophic factor levels (real-time quantitative polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA)); (c) retinal apoptotic rate (TUNEL); (d) retinal levels of reactive oxygen species and oxidative damage (ELISA); (e) electrical response of the retina (electroretinography); (f) pro-angiogenic and anti-angiogenic factor levels (RT-qPCR and ELISA); and (g) retinal blood vessels (angiography). Furthermore, 1, 4, 8 and 12 weeks post-MSC administration, the presence of donor cells in the retina and their differentiation into neural and perivascular-like cells were assessed (immunofluorescence and flow cytometry).</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>MSC administration completely prevented retinal ganglion cell loss. Donor cells remained in the vitreous cavity and did not differentiate into neural or perivascular-like cells. Nevertheless, they increased the intraocular levels of several potent neurotrophic factors (nerve growth factor, basic fibroblast growth factor and glial cell line-derived neurotrophic factor) and reduced the oxidative damage in the retina. Additionally, MSC administration has a neutral effect on the electrical response of the retina and did not result in a pathological neovascularization.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Intravitreal administration of adipose-derived MSCs triggers an effective cytoprotective microenvironment in the retina of diabetic mice. Thus, MSCs represent an interesting tool in order to prevent diabetic retinopathy.</jats:p> </jats:sec>
1Scopus© Citations 109 1
Some of the metrics are blocked by your
consent settings
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
(2016)
CRISTIAN HUMBERTO LABARCA SOLAR
;
Matthew J. Koster
;
Cynthia S. Crowson
;
Ashima Makol
;
Steven R. Ytterberg
4Scopus© Citations 147
Some of the metrics are blocked by your
consent settings
The Forgotten Role of Glucose Effectiveness in the Regulation of Glucose Tolerance
(2015)
Simmi Dube
;
Isabel Errazuriz-Cruzat
;
Ananda Basu
;
Rita Basu
15Scopus© Citations 37

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results